Issues & Trends

SJG SEJONG CO.,LTD. Reports Cumulative Third-Quarter Revenue of 1.5 Trillion Won… Operating Profit of 96.1 Billion Won

Up 8.1% and 14.2%, respectively, compared to the previous year

Kwon Oh Seok
2026-11-16 16:23:30
[Edaily Reporter Kwon Oh Seok ] Hyundai Motor Exhaust Systems Co., Ltd. ( SJG SEJONG CO.,LTD.(033530)), a company specializing in automotive exhaust systems, posted an upward trend in earnings despite a slowdown in the Chonbang growth of its upstream industries, thanks to a “selective focus” strategy for its global production hubs. By boldly divesting its unprofitable operations in China while concentrating its resources on its strong-performing bases in India, Mexico, and North America, the company achieved a qualitative improvement, posting an operating profit growth rate of 14.2%—significantly outpacing the revenue growth rate of 8.1%.
(Photo: SJG SEJONG CO.,LTD.)

According to SJG SEJONG CO.,LTD. on the 16th, the company’s cumulative consolidated revenue for the third quarter of this year totaled 1.5173 trillion won, an increase of approximately 8.1% compared to the same period last year. Cumulative operating profit for the same period surged 14.2% to 96.1 billion won (operating profit margin of 6.3%), demonstrating robust profitability.
The key to this strong performance lies in proactive supply chain rebalancing in response to shifting dynamics in the global automotive market. Even as the global automotive industry experienced a lull in demand, sales volumes at the company’s facilities in Mexico and India—where key customers are increasing their local production—rose significantly, driving revenue growth.
In addition, profitability was further strengthened by the stable profit contribution from its subsidiary, Asentech LTD., and extensive efforts to streamline overseas operations. SJG SEJONG CO.,LTD. has been implementing structural reforms by divesting chronically unprofitable overseas operations—such as the recent sale of its Yancheng Xuzhou subsidiary in China—and reallocating resources to high-profit, high-growth hubs.
Going forward, growth momentum is expected to be led by the North American hybrid market. This is because, as the “electric vehicle chasm” (a temporary stagnation in demand) persists in the global market, demand for hybrid vehicles—which are equipped with internal combustion engine-based exhaust systems—is surging.
In line with this trend, it is anticipated that once SJG SEJONG CO.,LTD.’s production facility in Savannah, Georgia—for which the company announced a new investment last month—is completed, the company’s market dominance and profitability in North America will both take a significant leap forward. This plant will serve as a forward base to support HyundaiMotor Group’s strategy of increasing hybrid vehicle production in North America and expanding local parts procurement, with mass production of the first batch scheduled to begin in August of next year.
SJG SEJONG CO.,LTD. official stated, “We are streamlining low-profit overseas operations to boost the profitability of our global business, while simultaneously making proactive investments in key markets with clear growth potential,” adding, “The effects of this business restructuring will have a positive impact on our performance not only in the fourth quarter but also next year and beyond, thereby supporting our growth momentum.”

Economy

Corporation

IT·Science

Economy

[Exclusive] CJ and HDC to Wind Down Biodegradable Plastics Business Launched Jointly After 4 Years

#HDC Hyundai EP and #CJ CheilJedang’s joint venture, CJ HDC BioSol (hereinafter “BioSol”), established to develop biodegradable plastic materials, has begun the process of dissolution. Analysts sugges…
2026-11-16 16:30:04

Corporation

'Balanced Growth in Fashion and Beauty' LF Reports 51.1 Billion Won in Q3 Operating Profit… Up 217%

LF achieved both revenue growth and improved profitability in the third quarter, driven by balanced growth across its in-house and imported fashion and beauty brands. LF(093050)According to the quarte…
2026-11-16 16:38:14

IT·Science

Olix Pharmaceuticals, Inc. Expands Development of Adipose Tissue-Targeted Weight-Loss Drug… Plans to File IND Application in the First Half of Next Year

RNA interference (RNAi) drug developer Olix Pharmaceuticals, Inc.(226950)is expanding its research and development of next-generation obesity treatments using adipose tissue-targeted RNAi technology. …
2026-11-16 16:35:03